Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan

An orphan medicinal product, eculizumab is approved in Japan and globally for treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab therapy can cause late complement pathway deficiencies that predispose patients to meningococcal infections. Although meningoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanimoto, Tetsuya, Kusumi, Eiji, Hosoda, Kazutaka, Kouno, Kaduki, Hamaki, Tamae, Kami, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990028/
https://www.ncbi.nlm.nih.gov/pubmed/24716834
http://dx.doi.org/10.1186/1750-1172-9-48

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990028/
https://www.ncbi.nlm.nih.gov/pubmed/24716834
http://dx.doi.org/10.1186/1750-1172-9-48

Ejemplares similares